Our research goals at NYU Langone’s Division of Gastroenterology and Hepatology are to provide access to the latest treatments in the pipeline to our patients and to advance knowledge of gastroenterology and hepatology through innovative basic science, translational research, and clinical trials. We aim to foster a spirit of scientific inquiry and innovation among faculty, fellows, and students.

Our researchers study the biology, prevention, diagnosis, and treatment of gastrointestinal (GI) and liver diseases. Among our current areas of research are the following:

• role of the gut microbiome in health and the pathogenesis of disease such as colorectal cancer, liver cancer, and fatty liver and other diseases
• role of GI infection and gut microbial dysbiosis in the pathogenesis of inflammatory bowel disease
• colorectal cancer prevention, including evaluation of sociodemographic and geographic disparities in colorectal cancer screening and outcomes, the comparative effectiveness of different screening strategies, and novel methods to increase screening adherence
• quality and innovations in enhanced technologies for colon cancer screening
• bariatric endoscopy outcomes in obesity and fatty liver disease
• clinical trials in all areas of liver disease, inflammatory bowel disease, colorectal cancer screening and prevention, and other GI conditions
• cirrhosis and hepatitis C infection